Azacitidine as a bridge to allogeneic hematopoietic cell transplantation in a pediatric patient with Fanconi anemia and acute myeloid leukemia

被引：6

作者：

Ding, Hilda ^{[1
]}

Hashem, Hasan ^{[1
]}

Cabral, Linda ^{[1
]}

Rangarajan, Hemalatha ^{[2
]}

Abusin, Ghada ^{[3
]}

Lazarus, Hillard M. ^{[4
]}

Abu-Arja, Rolla ^{[2
]}

机构：

[1] Case Med Ctr, Pediat Hematol Oncol & Bone Marrow Transplantat, Univ Hosp Rainbow Babies & Childrens Hosp, Cleveland, OH USA

[2] Nationwide Childrens Hosp, Pediat Hematol Oncol & Bone Marrow Transplant, Columbus, OH USA

[3] Univ Iowa, Childrens Hosp, Pediat Hematol Oncol & Bone Marrow Transplant, Iowa City, IA USA

[4] Univ Hosp Case Med Ctr, Dept Haematol & Med Oncol, Cleveland, OH USA

来源：

PEDIATRIC TRANSPLANTATION | 2017年 / 21卷 / 02期

关键词：

acute myeloid leukemia; azacitidine; donor lymphocyte infusion; Fanconi anemia; hematopoietic cell transplant; pediatric; CONVENTIONAL CARE REGIMENS; SALVAGE THERAPY; CHILDREN; AML; CHEMOTHERAPY; DECITABINE; RELAPSE; MDS;

D O I：

10.1111/petr.12870

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

HCT is the definitive therapy for patients with FA and AML. Conventional cytotoxic agents cause potential DNA damage, and currently, there is no established regimen for these patients prior to HCT. A 13-year-old male with FA and refractory AML was given azacitidine, achieved morphologic remission and underwent HCT. At 95 days after HCT, he relapsed. Azacitidine along with DLI was used as first salvage therapy. Azacitidine was overall well tolerated with minimal side effects. In patients with AML and FA, azacitidine can be considered an alternative to conventional chemotherapy.

引用

页数：3

共 50 条

[31] Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Myeloid Leukemia
Yalniz, Fevzi
Saliba, Rima
Greenbaum, Uri
Ramdial, Jeremy
Alousi, Amin
Joseph, Jacinth
Olson, Amanda
Alatrash, Gheath
Marin, David
Rezvani, Katayoun
Hosing, Chitra
Im, Jin
Shpall, Elizabeth
Mehta, Rohtesh
Qazilbash, Muzaffar
Popat, Uday
Oran, Betul
Champlin, Richard
Kebriaei, Partow
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S202 - S202
[32] Allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia and pulmonary mucormycosis
Schneidawind, D.
Nann, D.
Vogel, W.
Faul, C.
Fend, F.
Horger, M.
Kanz, L.
Bethge, W.
TRANSPLANT INFECTIOUS DISEASE, 2012, 14 (06) : E166 - E172
[33] Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis
Drozd-Sokolowska, Joanna
Karakulska-Prystupiuk, Ewa
Biecek, Przemyslaw
Kobylinska, Katarzyna
Piekarska, Agnieszka
Dutka, Magdalena
Waszczuk-Gajda, Anna
Madry, Krzysztof
Kopinska, Anna
Golos, Aleksandra
Gora-Tybor, Joanna
Szwedyk, Pawel
Bolkun, Lukasz
Czyz, Anna
Giebel, Sebastian
Basak, Grzegorz Wladyslaw
Dwilewicz-Trojaczek, Jadwiga
EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 107 (01) : 129 - 136
[34] Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
Craddock, Charles
Labopin, Myriam
Robin, Marie
Finke, Juergen
Chevallier, Patrice
Yakoub-Agha, Ibrahim
Bourhis, Jean Henri
Sengelov, Henrik
Blaise, Didier
Luft, Thomas
Hallek, Michael
Kroeger, Nicolaus
Nagler, Arnon
Mohty, Mohamad
HAEMATOLOGICA, 2016, 101 (07) : 879 - 883
[35] Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes
Yanada, Masamitsu
Konuma, Takaaki
Yamasaki, Satoshi
Kondo, Tadakazu
Fukuda, Takahiro
Shingai, Naoki
Sawa, Masashi
Ozawa, Yukiyasu
Tanaka, Masatsugu
Uchida, Naoyuki
Nakamae, Hirohisa
Katayama, Yuta
Matsuoka, Ken-ichi
Kimura, Takafumi
Kanda, Yoshinobu
Ichinohe, Tatsuo
Atsuta, Yoshiko
Yano, Shingo
BONE MARROW TRANSPLANTATION, 2021, 56 (05) : 1126 - 1133
[36] Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors
Liberatore, Carmine
Stanghellini, Maria Teresa Lupo
Lorentino, Francesca
Vago, Luca
Carrabba, Matteo Giovanni
Greco, Raffaella
Marktel, Sarah
Assanelli, Andrea
Farina, Francesca
Corti, Consuelo
Bernardi, Massimo
Peccatori, Jacopo
Sockel, Katja
Middeke, Jan Moritz
Schetelig, Johannes
Bergmann, Anika
Rautenberg, Christina
Ciceri, Fabio
Bornhaeuser, Martin
Schroeder, Thomas
Stoelzel, Friedrich
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
[37] Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia
Lipof, Jodi J.
Loh, Kah Poh
O'Dwyer, Kristen
Liesveld, Jane L.
CANCERS, 2018, 10 (06)
[38] Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia
Masamitsu Yanada
Satoshi Yamasaki
Takaaki Konuma
Shohei Mizuno
Naoyuki Uchida
Daishi Onai
Takahiro Fukuda
Masatsugu Tanaka
Yukiyasu Ozawa
Tetsuya Eto
Kazuhiro Ikegame
Masashi Sawa
Yuta Katayama
Toshiro Kawakita
Makoto Onizuka
Yoshinobu Kanda
Tatsuo Ichinohe
Yoshiko Atsuta
Shingo Yano
International Journal of Hematology, 2023, 117 : 398 - 408
[39] Successful Treatment of Behcet's Disease Associated with Acute Myeloid Leukemia with Myelodysplasia-related Changes Using Azacitidine and Tacrolimus before Allogeneic Hematopoietic Stem Cell Transplantation
Nakamura, Yukinori
Matsuguma, Masafumi
Tokunaga, Yoshihiro
Yamamoto, Kaoru
Tanaka, Mayumi
Tanaka, Yoshinori
Yujiri, Toshiaki
Tanizawa, Yukio
INTERNAL MEDICINE, 2017, 56 (10) : 1199 - 1202
[40] Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation
Ghobadi, Armin
Choi, Jaebok
Fiala, Mark A.
Fletcher, Theresa
Liu, Jingxia
Eissenberg, Linda G.
Abboud, Camille
Cashen, Amanda
Vij, Ravi
Schroeder, Mark A.
Pusic, Iskra
Stockerl-Goldstein, Keith
Jacoby, Meagan
Uy, Geoffrey
DiPersio, John
Westervelt, Peter
LEUKEMIA RESEARCH, 2016, 49 : 1 - 6

← 1 2 3 4 5 →